PMID- 16421966
OWN - NLM
STAT- MEDLINE
DCOM- 20060517
LR  - 20181113
IS  - 1673-1581 (Print)
IS  - 1673-1581 (Linking)
VI  - 7
IP  - 2
DP  - 2006 Feb
TI  - Dendritic cell therapy with improved outcome in glioma multiforme--a case report.
PG  - 114-7
AB  - Malignant gliomas are the most devastating tumors in clinical practice and have 
      poorest survival. Immunological treatment of such patients may likely increase 
      the survival and quality of life. Dendritic cells (DCs), most potent antigen 
      presenting cells in combination with oral chemotherapeutic agents may be tried 
      for patients giving consent to such treatment. We have successfully combined the 
      two therapies in an adult male patient who was on downhill course after being 
      operated on once with post operation chemotherapy and radiotherapy for glioma in 
      the left parietal area. He received five dendritic cell therapy vaccines in 
      combination with oral chemotherapy and responded dramatically having near normal 
      quality of life for an additional five months with this regime, increasing the 
      survival after operation to 11 months. This therapy is continuing with 
      radiological betterment of the lesion. The DCs are matured with antigen extracted 
      from wax embedded tissue at 6th day of culture. We feel that the treatment can be 
      given to more number of patients to establish its efficacy for the dreaded cancer 
      glioblastoma multiforme.
FAU - Khan, Jamal A
AU  - Khan JA
AD  - Microbiology Research Lab, C-38/Sector 20, Noida U.P. 201301, India. 
      cancerclinic2000@yahoo.com
FAU - Yaqin, Sharmin
AU  - Yaqin S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - J Zhejiang Univ Sci B
JT  - Journal of Zhejiang University. Science. B
JID - 101236535
RN  - 0 (Antigens)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigens/chemistry
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Brain/pathology
MH  - Brain Neoplasms/drug therapy/*therapy
MH  - *Cancer Vaccines
MH  - Combined Modality Therapy
MH  - Dendritic Cells/*metabolism
MH  - Glioma/drug therapy/*therapy
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Male
MH  - Middle Aged
MH  - Time Factors
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
PMC - PMC1363754
EDAT- 2006/01/20 09:00
MHDA- 2006/05/18 09:00
PMCR- 2006/02/01
CRDT- 2006/01/20 09:00
PHST- 2006/01/20 09:00 [pubmed]
PHST- 2006/05/18 09:00 [medline]
PHST- 2006/01/20 09:00 [entrez]
PHST- 2006/02/01 00:00 [pmc-release]
AID - 10.1631/jzus.2006.B0114 [doi]
PST - ppublish
SO  - J Zhejiang Univ Sci B. 2006 Feb;7(2):114-7. doi: 10.1631/jzus.2006.B0114.